Mass Spectrometry Advances in Analysis of Glioblastoma
Mass Spectrometry Reviews · 2025-07 · 44 (4) · 630-664
DOI: 10.1002/mas.21912 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mass Spectrometry Reviews, online erschienen am 11.11.2024. Verfasst von Sofian Al Shboul und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, Jordan. Hauptthemen laut MEDLINE: Glioblastoma, Mass Spectrometry, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 245 Literaturangaben. Gefördert von: Sofian Al Shboul is supported by Grants No. 785/48/2022 and 738/54/2022 provided by the Deanship of Scientific Research, The Hashemite University. Irena Dapic…, Program to strengthen young scientists MZ-2023.
Abstract (Originalsprache)
Some cancers such as glioblastoma (GBM), show minimal response to medical interventions, often only capable of mitigating tumor growth or alleviating symptoms. High metabolic activity in the tumor microenvironment marked by immune responses and hypoxia, is a crucial factor driving tumor progression. The many developments in mass spectrometry (MS) over the last decades have provided a pivotal tool for studying proteins, along with their posttranslational modifications. It is known that the proteomic landscape of GBM comprises a wide range of proteins involved in cell proliferation, survival, migration, and immune evasion. Combination of MS imaging and microscopy has potential to reveal the spatial and molecular characteristics of pathological tissue sections. Moreover, integration of MS in the surgical process in form of techniques such as DESI‐MS or rapid evaporative ionization MS has been shown as an effective tool for rapid measurement of metabolite profiles, providing detailed information within seconds. In immunotherapy‐related research, MS plays an indispensable role in detection and targeting of cancer antigens which serve as a base for antigen‐specific therapies. In this review, we aim to provide detailed information on molecular profile in GBM and to discuss recent MS advances and their clinical benefits for targeting this aggressive disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, Jordan.
- Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland, UK.
- Ruder Boskovic Institute, Zagreb, Croatia.
- University of Victoria-Genome BC Proteomics Centre, Victoria, British Columbia, Canada.
- Translational Neurosurgery, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
ORCID-Profile: Sofian Al Shboul, Renata Kobetic, David R Goodlett, Paul M Brennan, Ted Hupp, Irena Dapic
Förderung
- Sofian Al Shboul is supported by Grants No. 785/48/2022 and 738/54/2022 provided by the Deanship of Scientific Research, The Hashemite University. Irena Dapic…
- Program to strengthen young scientists MZ-2023
Zitieren
APA
Al Shboul, S., Singh, A., Kobetic, R., Goodlett, D. R., Brennan, P. M., Hupp, T., & Dapic, I. (2025). Mass Spectrometry Advances in Analysis of Glioblastoma. Mass Spectrometry Reviews, 44(4), 630-664. https://doi.org/10.1002/mas.21912
Vancouver
Al Shboul S, Singh A, Kobetic R, Goodlett DR, Brennan PM, Hupp T, et al. Mass Spectrometry Advances in Analysis of Glioblastoma. Mass Spectrometry Reviews. 2025;44(4):630-664. doi:10.1002/mas.21912
BibTeX
@article{AlShboul2025,
author = {Al Shboul, Sofian and Singh, Ashita and Kobetic, Renata and Goodlett, David R and Brennan, Paul M and Hupp, Ted and Dapic, Irena},
title = {Mass Spectrometry Advances in Analysis of Glioblastoma},
journal = {Mass Spectrometry Reviews},
year = {2025},
volume = {44},
number = {4},
pages = {630--664},
doi = {10.1002/mas.21912}
}
EUVIMED